CBLLNasdaqElectromedical & Electrotherapeutic ApparatusFiscal year ends December 31

Ceribell, Inc.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 10, 2026

$26.00+0.96 (+3.83%)

Close on Oct 19, 2026

Market cap: $988.83M
P/E (TTM): –
Dividend yield: –

Ceribell, Inc. income statement

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31
Revenue	89	65	45
Cost of Revenue	11	8.69	7.06
Gross Profit	78	57	38
Research & Development	19	14	9.00
Selling, General & Admin	118	83	59
Selling & Marketing	73	49	39
General & Administrative	44	34	20
Advertising Expenses	0.20	0.40	0.50
Operating Expenses	137	96	68
Operating Income	-58	-40	-30
Interest Expense	1.89	1.99	2.10
Other Non-Operating Income	6.88	2.74	2.64
Gain (Loss) on Sale of Assets	-0.10	-0.10	-0.18
Pretax Income	-53	-40	-29
Income Tax Expense	0	0	0.01
Net Income incl. Noncontrolling Interests	-53	-40	-29
Net Income	-53	-40	-29
EPS (Basic)(per share)	-1.46	-3.39	-5.56
EPS (Diluted)(per share)	-1.46	-3.39	-5.56
Shares Outstanding (Basic, Weighted)(shares)	37	12	5.30
Shares Outstanding (Diluted, Weighted)(shares)	37	12	5.30
EBITDA	-57	-39	-29

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, TTM

Gross margin: 88.9%
Operating margin: -68.6%
Net margin: -64.7%
Return on equity, FY2025: -30.8%

Financial strength

Current ratio: 9.18
Debt to equity: 0.16
Debt to assets: 12.0%
Cash to current liabilities: 189.9%

Valuation

P/E ratio: –
Price to sales: 9.70
Price to book: 7.71
Dividend yield: –